Imatinib mesylate-induced acute cytolytic hepatitis [2];Hépatite aiguë cytolytique induite par l'imatinib mesylate

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 10 I, 2004, Pages 918-919

  Rocca, Pierre ^a   El Jastimi, Saïd ^a   Troncy, Jacques ^b   Scoazec, Jean Yves ^b   Boucher, Alexandra ^b   Vial, Thierry ^b   Trepo, Christian ^a   Zoulim, Fabien ^a  

^a HÔTEL DIEU   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CHIMERIC ANTIBODY; HEXAQUINE; IMATINIB; ONCOPROTEIN; PAROXETINE; PLATELET DERIVED GROWTH FACTOR; STEM CELL FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE CYTOLYTIC HEPATITIS; ADULT; ASTHENIA; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; GASTROINTESTINAL STROMAL TUMOR; HEPATITIS; HUMAN; LETTER; METASTASIS; PHILADELPHIA 1 CHROMOSOME;

EID: 7044245483     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(04)95160-3     Document Type: Letter

References (9)

1. Heinrich MC, Griffeth DJ, Druker BJ, Wait CL, Oh KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-32.
2. Savage DG, Antman KH. Imatinib mesylate - A new oral targeted therapy. N Engl J Med 2002;346:683-93.
3. Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastro-intestinal stromal tumors. N Engl J Med 2002;347:472-80.
4. Elliott MA, Mesa RA, Tefferi A, Burton C, Azzi A, Kerridge I. Adverse events after imatinib mesylate therapy. N Engl J Med 2002;346:712-13.
5. Pindolia VK, Zarowitz BJ. Imatinib mesylate, the first molecularly targeted gene suppressor. Pharmacotherapy 2002;22:1245-65.
6. Lysen-Williamson K, Jarvis B. Imatinib. Drugs 2001;61:1765-76.
7. Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa K, et al. Imatinib mesylate induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002;16:2160-1.
8. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 2003;17:978-9.
9. Danan G. Atteintes hépatiques aiguës médicamenteuses. Qu'apportent les échelles diagnostiques. Gastroenterol Clin Biol 2003;27:(suppl):B21-5.